RHHBY 949 Exp: 08/15/09	HEALTHCARE - PHARMACEUTICAL XELODA - ROCHE WINNING PRIOR ART FOUND FOR 2 SEPARATE PATHS THAT CAN SHOW THE XELODA PATENT TO BE INVALID! Article One congratulates our latest winners! Advisors Anonymous and Magnum submitted prior art that can show that the U.S. patent for XELODA is invalid as verified by an independent law firm. The winning references disclose the substitution used to construct the N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine molecule as well as support for why the substitution would be made. Anonymous and Magnum will share the $25,000 Reward for this Study, demonstrating why they belong in the ranks of our Genius Advisors. Hoffman LaRoche has sued 2 companies for patent infringement to prevent them from selling a generic version of N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine (Xeloda®). The Article One community uncovered references for 2 separate paths that teach the claim elements, why the lead molecule would be selected, what results could be expected from substitutions to the lead molecule, and why a person of ordinary skill in the art at that time would have been motivated to make that change. The proprietary collection is available for license. View Details	$25,000.00 View Details Winning Advisors: Magnum Anonymous

Min 120 Exp: 01/29/09	TECHNOLOGY - TELEPHONE APPARATUS CELLPHONES - MINERVA WINNING STUDY, TWO SEPARATE PATHS TO INVALIDITY IDENTIFIED FOR DEFENSE AGAINST MINERVA INDUSTRIES' PATENT INFRINGEMENT LITIGATION! Article One is excited to announce our community's newest set of winning Advisors - Columbo, Singh and Ramesh - for their success in identifying two independent paths to invalidity. The Minerva Study uncovered new dramatic invalidating prior art that extensive traditional prior art searches didn’t produce AOP’s evidence has not been introduced in pending reexaminations. With so many Article One Advisors using different approaches, unique references unlikely to be found through traditional searching were uncovered. The references include foreign patents, detailed product announcements, product brochures and web pages. The proprietary collection is available for license. View Details	$50,000.00 View Details Winning Advisors: Singh Ramesh Columbo

LLY 269 Exp: 03/31/09	HEALTHCARE - PHARMACEUTICAL CYMBALTA/ELI LILLY WINNING PRIOR ART FOUND THAT CAN SHOW THE CYMBALTA PATENT TO BE INVALID! Article One congratulates our latest winner! Advisor Columbo submitted prior art that can show that the U.S. patent for CYMBALTA is invalid as verified by an independent law firm. His winning references disclose the substitutions used to construct the duloxetine molecule as well as support for why the substitutions would be made. Columbo will receive the $50,000 Reward for this Study, demonstrating why he is one of our Genius Advisors. Eli Lilly has sued 8 companies for patent infringement to prevent them from selling a generic version of duloxetine hydrochloride (Cymbalta®). The Article One community uncovered references that teach the claim elements, why the lead molecule would be selected, what results could be expected from substitutions to the lead molecule, and why a person of ordinary skill in the art at that time would have been motivated to make that change. The proprietary collection is available for license. View Details	$50,000.00 View Details Winning Advisors: Columbo

ACTI 457 Exp: 01/29/09	TECHNOLOGY - SOFTWARE MUSIC VIDEO GAMES - ACTIVISION Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

KNM 822 Exp: 01/29/09	TECHNOLOGY - SOFTWARE MUSIC VIDEO GAMES - KONAMI Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	PRIOR ART Advisors Earn Profit Sharing POINTS

SEPR 558 Exp: 03/31/09	HEALTHCARE - PHARMACEUTICAL XYZAL/SEPRACOR Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

MDT 650 Exp: 01/29/09	HEALTHCARE - MEDICAL & SURGICAL DEVICES INTRAVASCULAR STENT - MEDTRONIC Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

FRX 703 Exp: 01/29/09	HEALTHCARE - PHARMACEUTICAL NAMENDA - FOREST LABS Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

SNY 531 Exp: 06/15/09	HEALTHCARE - PHARMACEUTICAL AMBIEN CR/ SANOFI-AVENTIS Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

SEPR 926 Exp: 06/15/09	HEALTHCARE - PHARMACEUTICAL LUNESTA/ SEPRACOR Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

AZN 314 Exp: 03/31/09	HEALTHCARE - PHARMACEUTICAL CRESTOR - ASTRAZENECA WINNING PRIOR ART FOUND THAT CAN SHOW THE CRESTOR PATENT TO BE INVALID! Article One congratulates our latest winner! Advisor Columbo submitted prior art that can show that the US patent for Crestor is invalid as verified by an independent law firm, Darby and Darby, and an independent expert in medicinal chemistry. Columbo will receive a monetary award and join the ranks of our Genius Advisors. AstraZeneca has sued 9 companies for patent infringement to prevent them from selling a generic version of rosuvastatin calcium (Crestor®). The Article One community uncovered references that teach the claim elements, why the lead molecule would be selected, what results could be expected from substitutions to the lead molecule, and why a person of ordinary skill in the art at that time would have been motivated to make that change. View Details	$50,000.00 View Details Winning Advisors: Columbo

JSA 857 Exp: 03/15/09	TECHNOLOGY - SOFTWARE NETWORK-ACCESSIBLE ACCOUNT SYSTEM WINNING STUDY, TWO SEPARATE 102 PRIOR ART REFERENCES IDENTIFIED FOR DEFENSE AGAINST JSA TECHNOLOGY'S PATENT INFRINGEMENT LITIGATION! Article One is delighted to announce our community's newest set of winning Advisors -- Ramesh and Patented - for their success in identifying two independent paths to invalidity under the strongest level of invalidity evidence under "102 anticipation." Article One already has begun to license the proprietary collection, with law firm Davis Wright Tremaine, LLP first to license. The JSA Study uncovered new dramatic invalidating prior art that extensive traditional prior art searches didn’t produce. With so many Article One Advisors using different approaches, a wide variety of highest quality references were found, including two separate 102 invalidity references -- a U.S. patent, and obscure publications about a product offered in 1997. The proprietary collection is available for license to the community. View Details	$50,000.00 View Details Winning Advisors: Patented Ramesh

TKPHF 584 Exp: 01/29/09	HEALTHCARE - PHARMACEUTICAL ACTOPLUS MET - TAKEDA Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

NVS 802 Exp: 01/29/09	HEALTHCARE - PHARMACEUTICAL LOTREL - NOVARTIS Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

PPCO 933 Exp: 03/31/09	HEALTHCARE - PHARMACEUTICAL OPANA ER/PENWEST Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

TKPHF 632 Exp: 01/29/09	HEALTHCARE - PHARMACEUTICAL PREVACID - TAKEDA Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

WYE 171 Exp: 01/29/09	HEALTHCARE - PHARMACEUTICAL EFFEXOR XR - WYETH Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

WIN 222 Exp: 01/29/09	TECHNOLOGY - WIRELESS COMMUNICATION WIRELESS TRANSMISSIONS - WI-LAN Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes highly relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

PFE 995 Exp: 01/29/09	HEALTHCARE - PHARMACEUTICAL LIPITOR - PFIZER Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

Worlds 690 Exp: 03/15/09	TECHNOLOGY - SOFTWARE SYSTEM AND METHOD FOR ENABLING USERS TO INTERACT IN A VIRTUAL SPACE WINNING PRIOR ART FOUND THAT CAN SHOW THE WORLDS.COM PATENT TO BE INVALID ! Article One uncovered prior art including a primary reference for the independent claims and additional references for selected dependent claims. View Details	$50,000.00 Winning Adivisor: Anonymous

RIMM 442 Exp: 01/29/09	TECHNOLOGY - WIRELESS COMMUNICATION KEYBOARD - RIMM Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes highly relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

Wall 475 Exp: 01/29/09	HEALTHCARE - MEDICAL & SURGICAL DEVICES ANGIOPLASTY STENT – WALL Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes highly relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

APPL 949 Exp: 03/31/09	TECHNOLOGY - TELEPHONE APPARATUS IPHONE'S MULTI-TOUCH TECHNOLOGY - APPLE The Article One community uncovered the highest quality state of the art collection for Apple's multi-touch screen technology. The art is relevant to U.S. Patent No. 7,479,949 to show the state of the art from before the earliest invention date as well as through the filing date of the patent. Article One offers the prior art collection for the Apple 949 Patent Study for license to the industry. The prior art uncovered by the AOP community is fundamental information to allow members of industry to assess their freedom to operate, and evaluate potential licensing opportunities or acquisitions of patents in multi-touch screen technology for defensive purposes.	CLOSED Advisors Earn Profit Sharing POINTS

FIN 302 Exp: 06/15/09	TECHNOLOGY - SOFTWARE SECURITY FOR FINANCIAL TRANSACTIONS Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collection includes relevant references and is available for license.	CLOSED Advisors Earn Profit Sharing POINTS

MRK 473 Exp: 02/20/09	HEALTHCARE - PHARMACEUTICAL SINGULAIR - MERCK FROSST NEW PRIOR ART IDENTIFIED FOR MERCK'S SINGULAIR U.S. PATENT! Article One congratulates our two winning Advisors! Merck sued Teva for patent infringement to prevent Teva from making a generic version of SINGULAIR, with Merck's U.S. patent expiring in 2012 and $4.3 billion 2008 worldwide sales for SINGULAIR. View Details	$50,000.00 View Winning Art 2 Winning Advisors: AEKall ARTIOREL

RMBS 184 Exp: 02/20/09	TECHNOLOGY - SEMICONDUCTORS SEMICONDUCTORS - RAMBUS Article One received highly relevant prior art submissions for some of the Rambus patents. View Details	CLOSED Advisors Earn Profit Sharing POINTS

LSI 335 Exp: 01/29/09	TECHNOLOGY - SEMICONDUCTORS SEMICONDUCTORS - LSI WINNING PRIOR ART FOUND TO INVALIDATE LSI's U.S. PATENT! LSI's U.S. patent asserted in the International Trade Commission against 20 defendants to block imports of semiconductors used in a "wide array of products" as described by LSI is invalid. View Details	$50,000.00 View Winning Art Winning Advisors: RickyJames Ritwik Haferi

NSM 440 Exp: 01/29/09	TECHNOLOGY - SEMICONDUCTORS SEMICONDUCTORS - NATIONAL SEMICONDUCTOR Based on the response of the Article One community, the validity of the Study patents is not impacted by the Article One community research. View Details	CLOSED Advisors Earn Profit Sharing POINTS

RHHBY 938 Exp: 01/29/09	HEALTHCARE - PHARMACEUTICAL BONIVA - ROCHE Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing.	CLOSED Advisors Earn Profit Sharing POINTS

WYE 579 Exp: 01/29/09	HEALTHCARE - PHARMACEUTICAL PROTONIX - WYETH Article One Advisors submitted prior art relevant to this Study. The Article One prior art is not conclusive about patent validity. Advisors can continue to submit prior art to this Study and the prior art will be further considered for relevance and AOP profit sharing.	CLOSED Advisors Earn Profit Sharing POINTS

GRMN 873 Exp: 01/29/09	TECHNOLOGY - WIRELESS COMMUNICATION GPS GRAPHICAL INTERFACE - SPT/GARMIN WINNING STUDY, PRIOR ART IDENTIFIED FOR GARMIN'S DEFENSE AGAINST SP TECHNOLOGY'S PATENT INFRINGEMENT LITIGATION! Article One is delighted to announce our community's first winning Advisors - RickyJames and Patented - for their success in identifying winning prior art for this Study. RickyJames was first to submit his winning prior art and so earns $35,000.00. Patented was second to submit the winning prior art, earning $15,000.00. RickyJames and Patented also join the ranks of Genius Advisors and are each awarded 500 profit sharing Points. The determination of winners was based on Article One’s analysis, including review and analysis of outside counsel, leading Article One to reach the opinion that the prior art is invalidating because it teaches what is claimed in the subject patent U.S. Patent No. 6,784,873 B1. Article One believes that the claimed inventions would have been obvious to persons of ordinary skill in the relevant art at the time of the inventions. View Details	$50,000.00 View Details 2 Winning Advisors: RickyJames Patented

Information on Article One does not constitute patent law, investment, securities or trading advice.